Selected article for: "decreased lymphocyte and lymphocyte count"
Author: Ying Huang; Rui Yang; Ying Xu; Ping Gong
Title: Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China
  • Document date: 2020_2_29
    • ID: 9hh17k86_45
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.27.20029009 doi: medRxiv preprint the increased CRP, PCT concentration and decreased lymphocyte count from admission to death (Supplementary Figure 2) , which may represent more prominent inflammation in severe patients. Therefore, intravenous glucocorticoids therapy, intravenous immunoglobulin therapy and interferon-alpha (α-IFN) aeroso.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.27.20029009 doi: medRxiv preprint the increased CRP, PCT concentration and decreased lymphocyte count from admission to death (Supplementary Figure 2) , which may represent more prominent inflammation in severe patients. Therefore, intravenous glucocorticoids therapy, intravenous immunoglobulin therapy and interferon-alpha (α-IFN) aerosol inhalation were also used to restore homeostasis, without solid evidence. To our knowledge, there is still no specific medicine for COVID-19 till now. Clinical trials on promising regimens for COVID-19, such as remdesivir, lopinavir, and chloroquine phosphate are ongoing, which shed light on conquering the COVID-19 epidemic 12 .

    Search related documents:
    Co phrase search for related documents
    • aerosol inhalation and clinical trial: 1, 2, 3, 4, 5
    • aerosol inhalation and immunoglobulin therapy: 1
    • aerosol inhalation and lymphocyte count: 1
    • aerosol inhalation and severe patient: 1
    • chloroquine phosphate and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • chloroquine phosphate and severe patient: 1
    • chloroquine phosphate and specific medicine: 1, 2
    • clinical trial and homeostasis restore: 1
    • clinical trial and immunoglobulin therapy: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and increase crp: 1, 2, 3, 4
    • clinical trial and intravenous immunoglobulin therapy: 1, 2, 3
    • clinical trial and light shed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical trial and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • clinical trial and pct concentration: 1
    • clinical trial and prominent inflammation: 1
    • clinical trial and promise clinical trial: 1, 2, 3, 4, 5
    • clinical trial and severe patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical trial and solid evidence: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical trial and specific medicine: 1, 2, 3, 4, 5